-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imago BioSciences (NASDAQ:IMGO) Trading 8.3% Higher
Imago BioSciences (NASDAQ:IMGO) Trading 8.3% Higher
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating)'s stock price traded up 8.3% during mid-day trading on Thursday . The company traded as high as $16.12 and last traded at $16.12. 1 shares traded hands during trading, a decline of 100% from the average session volume of 108,936 shares. The stock had previously closed at $14.88.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reduced their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Price Performance
The business's 50-day moving average price is $16.25 and its two-hundred day moving average price is $17.12. The company has a market capitalization of $540.18 million, a price-to-earnings ratio of -9.24 and a beta of 2.48.
Insider Activity
In other news, insider Jennifer Peppe sold 5,598 shares of Imago BioSciences stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.41, for a total value of $108,657.18. Following the completion of the sale, the insider now directly owns 148,809 shares in the company, valued at $2,888,382.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 8,168 shares of company stock worth $155,402. Corporate insiders own 14.90% of the company's stock.Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences during the first quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock worth $30,000 after buying an additional 809 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Imago BioSciences during the first quarter worth $41,000. Legal & General Group Plc increased its holdings in shares of Imago BioSciences by 46.2% during the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after buying an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the second quarter worth $119,000. 99.50% of the stock is currently owned by institutional investors and hedge funds.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Featured Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating)'s stock price traded up 8.3% during mid-day trading on Thursday . The company traded as high as $16.12 and last traded at $16.12. 1 shares traded hands during trading, a decline of 100% from the average session volume of 108,936 shares. The stock had previously closed at $14.88.
納斯達克交易代碼：IMGO-GET週四午盤，Imago BioSciences，Inc.股價上漲8.3%，盤中一度漲至16.12美元，最新報16.12美元。盤中成交量為1美元，較108,936股的平均成交量下跌一倍。此前該股收盤價為14.88美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, HC Wainwright reduced their price objective on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, August 16th.
另外，HC Wainwright將Imago BioSciences的目標價從36.00美元下調至35.00美元，並在8月16日(星期二)的一份報告中為該公司設定了“買入”評級。
Imago BioSciences Price Performance
Imago BioSciences性價比
The business's 50-day moving average price is $16.25 and its two-hundred day moving average price is $17.12. The company has a market capitalization of $540.18 million, a price-to-earnings ratio of -9.24 and a beta of 2.48.
該業務的50日移動均線價格為16.25美元，200日移動均線價格為17.12美元。該公司市值為5.4018億美元，市盈率為-9.24倍，貝塔係數為2.48。
Insider Activity
內幕活動
Institutional Inflows and Outflows
機構資金流入和流出
Institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences during the first quarter valued at approximately $28,000. Ameritas Investment Partners Inc. increased its holdings in shares of Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company's stock worth $30,000 after buying an additional 809 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Imago BioSciences during the first quarter worth $41,000. Legal & General Group Plc increased its holdings in shares of Imago BioSciences by 46.2% during the second quarter. Legal & General Group Plc now owns 6,098 shares of the company's stock worth $81,000 after buying an additional 1,926 shares in the last quarter. Finally, Credit Suisse AG acquired a new position in shares of Imago BioSciences during the second quarter worth $119,000. 99.50% of the stock is currently owned by institutional investors and hedge funds.
機構投資者最近增持或減持了該公司的股份。紐約大都會人壽保險公司在第一季度收購了Imago BioSciences的一個新頭寸，價值約為2.8萬美元。今年第一季度，ameritas Investment Partners Inc.增持的Imago BioSciences股票增加了108.3%。Ameritas Investment Partners Inc.現在持有1,556股該公司股票，價值30,000美元，該公司在上個季度又購買了809股。合併銀行在第一季度收購了價值4.1萬美元的Imago BioSciences股票的新頭寸。Legal&General Group Plc在第二季度增持了Imago BioSciences的股票46.2%。Legal&General Group Plc現在持有該公司6,098股股票，價值81,000美元，上個季度又購買了1,926股。最後，瑞士信貸股份公司在第二季度收購了Imago BioSciences價值11.9萬美元的新頭寸。該公司99.50%的股票目前由機構投資者和對衝基金持有。
About Imago BioSciences
關於Imago BioSciences
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences，Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品，LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat，正在進行第二階段臨牀試驗，用於治療骨髓增生性腫瘤和慢性骨髓癌，如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- These Two Undervalued Stocks Are Ready To Rocket Higher
- Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
- GameStop Stock Just Flashed A Buy Signal
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 安相能源有足夠的動力繼續提高動力嗎？
- 獨一無二的氫燃料電池庫存
- 這兩隻被低估的股票已經做好了進一步衝高的準備
- 化工和化肥庫存中是否隱藏着寶藏？
- GameStop股票剛剛閃爍了買入信號
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧